Efficacy and safety of trabectedin in metastatic uterine leiomyosarcoma

Trabectedin confers clinical benefit in patients with recurrent/metastatic uLMS, given after failure to an anthracycline-based regimen being comparable to ...

Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic ...

Trabectedin demonstrates superior disease control versus conventional dacarbazine in patients who have advanced liposarcoma and leiomyosarcoma after they ...

Efficacy and safety of trabectedin or dacarbazine for the treatment of ...

Toxicities were consistent with the well-characterized profiles of both treatments. Conclusions: Among patients with uterine LMS, treatment with trabectedin ...

Efficacy and safety of trabectedin or dacarbazine in patients with ...

Trabectedin demonstrated significantly improved disease control in leiomyosarcoma and liposarcoma patients in a global phase 3 trial (NCT01343277 ).

Results of a Phase III Randomized Multicenter Clinical Trial

Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase ...

Efficacy and safety of trabectedin or dacarbazine in patients with ...

Efficacy and safety of trabectedin or dacarbazine in patients with advanced uterine leiomyosarcoma after failure of anthracycline-based chemotherapy ...

Efficacy and safety of trabectedin for patients with unresectable and ...

At an initial dose of 1.2 mg/m2 (applied only in Japan), trabectedin has clinically meaningful benefits for patients with ...

Efficacy and safety of trabectedin in metastatic uterine leiomyosarcoma

The primary endpoint was progression-free survival (PFS). Results Median PFS and overall survival (OS) since starting trabectedin treatment were 5.4 (95%CI: 3.5 ...

A phase II randomised (calibrated design) study on the activity of the ...

Patients with recurrent/metastatic uterine leiomyosarcoma (U-LMS) have a dismal prognosis. This phase II study aims to evaluate trabectedin ...

Efficacy and safety of trabectedin or dacarbazine in patients with ...

Patients with advanced uterine leiomyosarcoma received trabectedin or dacarbazine.•Trabectedin significantly improved progression-free survival vs ...

Efficacy and safety of trabectedin in patients with advanced or ...

Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: ...

Clinical outcomes and safety with trabectedin therapy in patients ...

L-sarcoma patients exhibited longer, OS compared with other histologies [16.2 months (95% confidence interval (CI) 14.1–19.5) versus 8.4 months (95% CI 7.1–10.7)] ...

a randomised, multicentre, open-label phase 3 trial - The Lancet

Metastatic leiomyosarcomas have a poor prognosis, and currently doxorubicin alone is used as the standard first-line treatment. Doxorubicin ...

Long-Lasting Response to Trabectedin in a Patient with Metastatic ...

Efficacy and safety of trabectedin or dacarbazine in patients with advanced uterine leiomyosarcoma after failure of anthracycline-based ...

Trabectedin Significantly Slows Progression in Uterine ... - OncLive

Patients with uterine leiomyosarcoma who received trabectedin had a median PFS of 4.0 months versus 1.5 months with dacarbazine, almost ...

Safety and Efficacy of the Combination Lurbinectedin plus ...

While cytotoxic chemotherapy is the standard first-line treatment for patients with metastatic soft-tissue sarcoma (STS), clinical outcomes ...

[PDF] Efficacy and Safety of Trabectedin or Dacarbazine for ...

Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase ...

Long-lasting activity of trabectedin in refractory uterine ...

... metastatic uterine leiomyosarcoma ... Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma ...

Trabectedin Offers Third-Line Option in Uterine Leiomyosarcoma

A subgroup analysis of the phase III SAR-3007 trial demonstrating the efficacy of trabectedin (Yondelis) in patients with advanced uterine ...

A single-arm multicentre phase II trial of doxorubicin in combination ...

In this homogeneous series of 107 patients with advanced/metastatic U-LMSs and ST-LMSs, efficacy results of trabectedin plus doxorubicin in ...